Pamela M Vacek1, Joan M Skelly. 1. Medical Biostatistics Unit, College of Medicine, University of Vermont, Burlingon, Vermont; Department of Pathology, College of Medicine, University of Vermont, Burlingon, Vermont; Vermont Cancer Center, University of Vermont and Fletcher Allen Health Care, Burlington, Vermont.
Abstract
OBJECTIVES: To prospectively examine how age and comorbidity affect screening mammography use, cancer detection, and overall survival. DESIGN: Prospective, with median follow-up of 10.2 years. SETTING: A population-based cohort of Vermont women with data in the Vermont Breast Cancer Surveillance System. PARTICIPANTS: Women aged 70 and older with no history of breast cancer (N = 20,697). MEASUREMENTS: Rates of screening, diagnostic procedure use, and breast cancer diagnosis were examined according to age and comorbidity. The effect of breast cancer on overall survival was assessed in relation to detection mode, tumor characteristics, and treatment. RESULTS: Screening declined 9% per year after age 70 and 18% with each unit increase in comorbidity score, with corresponding increases in clinically detected breast cancer. Invasive cancer was associated with greater overall mortality (screen detected: hazard ratio (HR) = 1.22, 95% confidence interval (CI) = 1.07-1.40; clinically detected: HR = 1.68, 95% CI = 1.43-1.96). The latter HR reflects a much greater absolute risk of death for women in a population with high baseline mortality. Use of breast-conserving surgery as the only treatment for Stage I cancer increased markedly with age and was associated with shorter overall survival than radiation or mastectomy (relative risk = 2.23, 95% CI = 1.42-3.47). CONCLUSION: Lower screening mammography use by older women is associated with more clinically detected breast cancers, which are associated with poorer survival. Treatment received for early-stage cancer influences the effect of screening on survival.
OBJECTIVES: To prospectively examine how age and comorbidity affect screening mammography use, cancer detection, and overall survival. DESIGN: Prospective, with median follow-up of 10.2 years. SETTING: A population-based cohort of Vermont women with data in the Vermont Breast Cancer Surveillance System. PARTICIPANTS: Women aged 70 and older with no history of breast cancer (N = 20,697). MEASUREMENTS: Rates of screening, diagnostic procedure use, and breast cancer diagnosis were examined according to age and comorbidity. The effect of breast cancer on overall survival was assessed in relation to detection mode, tumor characteristics, and treatment. RESULTS: Screening declined 9% per year after age 70 and 18% with each unit increase in comorbidity score, with corresponding increases in clinically detected breast cancer. Invasive cancer was associated with greater overall mortality (screen detected: hazard ratio (HR) = 1.22, 95% confidence interval (CI) = 1.07-1.40; clinically detected: HR = 1.68, 95% CI = 1.43-1.96). The latter HR reflects a much greater absolute risk of death for women in a population with high baseline mortality. Use of breast-conserving surgery as the only treatment for Stage I cancer increased markedly with age and was associated with shorter overall survival than radiation or mastectomy (relative risk = 2.23, 95% CI = 1.42-3.47). CONCLUSION: Lower screening mammography use by older women is associated with more clinically detected breast cancers, which are associated with poorer survival. Treatment received for early-stage cancer influences the effect of screening on survival.
Authors: R Van Harrison; Nancy K Janz; Robert A Wolfe; Philip J Tedeschi; Xuelin Huang; Laurence F McMahon Journal: Cancer Date: 2003-03-01 Impact factor: 6.860
Authors: R Ballard-Barbash; S H Taplin; B C Yankaskas; V L Ernster; R D Rosenberg; P A Carney; W E Barlow; B M Geller; K Kerlikowske; B K Edwards; C F Lynch; N Urban; C A Chrvala; C R Key; S P Poplack; J K Worden; L G Kessler Journal: AJR Am J Roentgenol Date: 1997-10 Impact factor: 3.959
Authors: Lennarth Nyström; Ingvar Andersson; Nils Bjurstam; Jan Frisell; Bo Nordenskjöld; Lars Erik Rutqvist Journal: Lancet Date: 2002-03-16 Impact factor: 79.321
Authors: Gary Ko; Julie Hallet; Katarzyna J Jerzak; Wing Chan; Natalie Coburn; Victoria Barabash; Frances C Wright; Nicole J Look Hong Journal: Ann Surg Oncol Date: 2022-10-18 Impact factor: 4.339
Authors: Jessica L Krok-Schoen; James L Fisher; Ryan D Baltic; Electra D Paskett Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-15 Impact factor: 4.254
Authors: Andrew McGuire; James A L Brown; Carmel Malone; Ray McLaughlin; Michael J Kerin Journal: Cancers (Basel) Date: 2015-05-22 Impact factor: 6.639
Authors: Olive Mbah; Jean G Ford; Miaozhen Qiu; Jennifer Wenzel; Lee Bone; Janice Bowie; Ahmed Elmi; Jimmie L Slade; Michele Towson; Adrian S Dobs Journal: BMC Cancer Date: 2015-11-16 Impact factor: 4.430
Authors: Nam P Nguyen; Ulf Karlsson; Eromosele Oboite; Julio Alvarenga; Juan Godinez; Alice Zamagni; Micaela Motta; Satya Bose; Vincent Vinh-Hung Journal: Transl Cancer Res Date: 2020-01 Impact factor: 1.241